Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BPH Global
Its shares trade on ASX under the ticker BP8.AX. It has been listed since 13 June 2000.
BPH Global Ltd. engages on using stem cell technology to grow and extract plant essence. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-06-13. The firm is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. The firm focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. The firm produces its products through various plants, which include Caulerpa lentillifera, Dendrobium officinale, Resina and Cannabis sativa. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, SCU Southeast Asia Sdn Bhd, SCU (HK) Ltd, Yunnan Huafang Industrial Hemp Co Ltd and SCU-RY Farm Pte Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jun 2000
- Website
- scu.com.sg ↗
Leadership
Pay as last reported
- Mr. Paul StephensonNon-Executive Independent Chairman of the Board
- Mr. Chow-Yee KohChief Financial Officer, since 2014
- Mr. Matthew LeonardManaging Director, Executive Director, since 2023
- Mr. Francesco CannavoPart Time Executive Director, since 2021
- Mr. Belinda CleminsonJoint Company Secretary
- Ms. Shelby ColemanJoint Company Secretary
- Mr. Justyn StedwellCompany Secretary
- Mr. Michael HuangNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on biotechnology and plant-based products including CBD and seaweed.
- Headquartered in Sydney with operations in Singapore, Australia, Southeast Asia, and China.
- Owns subsidiaries in multiple regions including Singapore, Hong Kong, and China.
Weaknesses
- IPO date is 2000-06-13, indicating a long history but potential outdated business model.
- Website provided (scu.com.sg) appears to be for a different company (SCU) not BPH Global Ltd.
- Source description mentions using stem cell technology for plant essence, which is not typical for biotechnology firms.
Opportunities
- Growing global market for plant-based protein and nutraceutical products.
- Expansion into Traditional Chinese Medicine-based health outcomes in Asian markets.
- Potential for CBD product commercialization in food and healthcare industries.
Threats
- Unreliable source description may lead to misinformation about company operations.
- Website mismatch could confuse investors and customers.
- Stem cell technology application for plant essence may face skepticism in the industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.